Trial Profile
Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination Regimen(s) as Compared to a Reference Combination Regimen(s) in Antiretroviral-Experienced HIV-Infected Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Ritonavir; Saquinavir
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Jun 2009 New trial record.